ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Enduro Life Sciences second quarter 2023 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Thank you, operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to NDRA's second quarter 2023 business update and financial results conference call. Earlier today, NDRA issued a press release on this topic. and also issued a news release announcing the submission of a de novo request for its TAIS system to the U.S. FDA, both of which are available in the investor section of NDRA's website. Before we begin, please note that today's discussion will include forward-looking statements. All statements by management other than statements of historical facts include statements regarding the company's strategies, financial condition, operations, costs, plans and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities, and expectations regarding regulatory processes, receipt of required regulatory clearances, and product launches, are forward-looking statements. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward-looking statements. Please refer to the company's Form 10-K for the 2022 fiscal year and subsequen...